New Phase II/III trial for ivonescimab starts in US to treat advanced biliary tract cancer.

Akeso and Summit Therapeutics announced a new Phase II/III clinical trial, EA2251, in collaboration with ECOG-ACRIN to test ivonescimab combined with chemotherapy against current immunotherapies for advanced biliary tract cancer. This marks the seventh international registrational trial for ivonescimab, following positive results from a Phase III study in China showing improved overall survival. The US trial aims to establish ivonescimab as a superior first-line treatment option, with results expected to advance global approval and patient access. The study is set to begin site activations in Q4 2026, highlighting ongoing efforts to improve outcomes in this hard-to-treat cancer.

As of Oct 21, 2026 19:51 WIB, Summit Therapeutics Inc (SMMT) shares are trading at USD 16.28 on Pluang, showing a 1.18% increase for the day. The stock has a market capitalization of $12.84 billion and an enterprise value of $12.17 billion. Pluang investors currently show full buying interest with 0% sell orders, highlighting strong demand for SMMT amid its ongoing clinical developments.